Related Experiment Video

Updated: May 16, 2026

Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors

Kivanç Birsoy1, Tim Wang, Richard Possemato

  • 1Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA.

Nature Genetics
|December 4, 2012
PubMed

Insights

Researchers identified MCT1 as crucial for 3-bromopyruvate (3-BrPA) uptake and cancer cell sensitivity. This finding suggests MCT1 levels could predict 3-BrPA effectiveness, aiding targeted cancer therapy development.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Oncogenic transformation alters cellular metabolism, often upregulating glycolysis.
  • Targeting glycolytic enzymes is a strategy for anticancer therapy.
  • 3-bromopyruvate (3-BrPA) is a glycolysis inhibitor with an unclear mechanism of action.

Purpose of the Study:

  • To identify mechanisms of resistance to 3-bromopyruvate (3-BrPA).
  • To elucidate the role of specific genes in 3-BrPA sensitivity.
  • To explore the potential of targeting transporters for cancer drug delivery.

Main Methods:

  • Genome-wide haploid genetic screen to identify 3-BrPA resistance genes.
  • Assessing 3-BrPA uptake and sensitivity in cancer cells.
  • Measuring SLC16A1 mRNA levels as a predictor of drug sensitivity.
  • Evaluating the effect of MCT1 expression on tumor xenografts in vivo.

Main Results:

  • The gene SLC16A1, encoding the monocarboxylate transporter 1 (MCT1), was identified as the primary determinant of 3-BrPA sensitivity.
  • MCT1 is essential and sufficient for 3-BrPA cellular uptake.
  • Elevated SLC16A1 mRNA levels correlate with 3-BrPA sensitivity and are highest in glycolytic cancer cells.
  • Enhanced MCT1 expression in resistant cells restored sensitivity to 3-BrPA in vivo.

Conclusions:

  • MCT1 is a key mediator of 3-BrPA sensitivity in cancer cells.
  • SLC16A1 mRNA levels can serve as a biomarker for predicting 3-BrPA efficacy.
  • Exploiting cancer-specific transporter selectivity offers a strategy for targeted drug delivery to tumors.

More Related Videos

MitoCeption: Transferring Isolated Human MSC Mitochondria to Glioblastoma Stem Cells11:13

MitoCeption: Transferring Isolated Human MSC Mitochondria to Glioblastoma Stem Cells

Published on: February 22, 2017

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Secondary Active Transport01:32

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
Secondary Active Transport01:55

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...